Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Revvity Omics, |
RCV001780501 | SCV002019298 | pathogenic | not provided | 2019-07-21 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002482305 | SCV002775085 | likely pathogenic | Congenital myasthenic syndrome 4A; Congenital myasthenic syndrome 4C; Congenital myasthenic syndrome 4B | 2022-02-01 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV003470898 | SCV004214249 | pathogenic | Congenital myasthenic syndrome 4A | 2023-06-16 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV003470898 | SCV005834435 | uncertain significance | Congenital myasthenic syndrome 4A | 2024-05-20 | criteria provided, single submitter | clinical testing | This sequence change results in a frameshift in the CHRNE gene (p.Ala477Profs*30). While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 17 amino acid(s) of the CHRNE protein and extend the protein by 12 additional amino acid residues. This variant is present in population databases (no rsID available, gnomAD 0.003%). This frameshift has been observed in individual(s) with CHRNE-related conditions (PMID: 30369941). ClinVar contains an entry for this variant (Variation ID: 1322081). Experimental studies and prediction algorithms are not available or were not evaluated, and the functional significance of this variant is currently unknown. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Prevention |
RCV004738379 | SCV005361202 | likely pathogenic | CHRNE-related disorder | 2024-08-26 | no assertion criteria provided | clinical testing | The CHRNE c.1429delG variant is predicted to result in a frameshift and premature protein termination (p.Ala477Profs*30). This variant has been reported in the compound heterozygous state in an affected individual with phenotypes consistent with CHRNE-related myasthenic syndrome (Theunissen et al. 2018. PubMed ID: 30369941). This variant is reported in 0.0028% of alleles in individuals of European (Non-Finnish) descent in gnomAD. Frameshift variants in CHRNE are expected to be pathogenic. This variant is interpreted as likely pathogenic. |